Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (2485)	1/6/2001 1:24:28 PM
From: scaram(o)uche	Respond to of 52153

Gorgeous, thanks. New math...... 24 plus 3 equals 10.

To: smh who wrote (2485)	1/6/2001 6:44:35 PM
From: Londo	Read Replies (1) \| Respond to of 52153

Another one I thought that could be added to your list is that Incyte owns 19.8% of Diadexus, which is apparantly trying to go public. This holding will get diluted after the IPO, if it occurs. No clue to what a potential valuation should be. freedgar.com

To: smh who wrote (2485)	1/8/2001 7:02:40 AM
From: smh	Read Replies (5) \| Respond to of 52153

Revised "Cross" portfolio (base 12/31/00) siliconinvestor.com Primary / Sub MC/MC % owned $ owned NBSC / DGI 28 / xx 82% xxx BTRN / SCS 102 / xx 30% xxx CEGE / ABGX 778 / 4828 10.5% 507 CNCT / ITMN 135 / 1066 4.2% 45 STEM / Modex 52 / 180 9.0% 16.4 MCDE / Iconix 47 / xxx 32% xxx RZYM / Atugen AG 220 / xxx 32% xxx TXB / Revotar Bio. AG 352 / xxx 55% xxx KDUS / Axiom 9.5 / 15 (est.) 20% 3.0 TRPS / ARNA 77 / 352 9.4% 33 AVM / CYTO 17.8/ 178 1.58% 2.8 AXPH / DPII 209 / 289 31% 90 SMH